Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

  • End date
    Apr 16, 2024
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 18 November 2021
chemotherapy regimen
creatinine clearance rate


Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for this study. All the eligible patients receive three cycles of induction chemotherapy (docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides, camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the first day of induction chemotherapy. We aim to evaluate the three years failure free survival of these patients by the combination of camrelizumab with curative radiotherapy and chemotherapy.

Condition camrelizumab, concurrent chemotherapy, Tomotherapy, Chemotherapy, Paranasal Sinus Cancer, Nasal Cavity Cancer, Induction Chemotherapy
Treatment Camrelizumab
Clinical Study IdentifierNCT05114707
SponsorSun Yat-sen University
Last Modified on18 November 2021


Yes No Not Sure

Inclusion Criteria

histologically confirmed squamous cancer of nasal cavity and paranasal sinuses
T4bN0-3M0 (AJCC8th) or unresectable lymph nodes or refusal of surgery
NE 1.510E9/L, HGB 100g/L and PLT 10010E9/L
ALT 1.5 upper limit of normal (ULN), AST 1.5ULN and bilirubin 1.5ULN
creatinine clearance rate 60 ml/min (calculated by Cockcroft-Gault)

Exclusion Criteria

older than 65 or younger than 18
HBsAg (+) and HBV DNA >110E3 copiers /mL
HCV (+)
HIV (+)
autoimmune diseases
interstitial lung diseases
had other cancers before
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note